Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9820948 | 0.89 | SIGMAR1 (0.55) | SLC6A3SIGMAR1MAOALTA4HHRH3 | |
| SCHEMBL9442022 | 0.88 | SIGMAR1 (0.60) | SLC6A3SIGMAR1LTA4HHRH3 | |
| SCHEMBL688048 | 0.81 | SIGMAR1 (0.48) | SLC6A3SIGMAR1HRH3NPC1TDP1 | |
| SCHEMBL14952674 | 0.76 | SLC6A3 (0.52) | SLC6A3SIGMAR1MAOAHRH3HTR1A | |
| SCHEMBL1514871 | 0.75 | SIGMAR1 (0.50) | SLC6A3SIGMAR1HRH3ACHE | |
| SCHEMBL2876271 | 0.74 | SLC6A3 (1.00) | SLC6A3SIGMAR1LTA4HHRH3HTR1A | |
| SCHEMBL11922748 | 0.72 | SIGMAR1 (1.00) | SLC6A3SIGMAR1LTA4HHRH3HTR1A | |
| Iodide SCHEMBL3691021 | 0.72 | SLC6A3 (0.96) | SLC6A3SIGMAR1LTA4HHRH3HTR1A | |
| 1-Phenethylpiperidine SCHEMBL4054824 | 0.72 | SIGMAR1 (1.00) | SLC6A3SIGMAR1LTA4HHRH3HTR1A | |
| SCHEMBL11589061 | 0.72 | SIGMAR1 (1.00) | SLC6A3SIGMAR1LTA4HHRH3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507753-B2 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1466904-A1 | BIARYL COMPOUND AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| CN-1035670-C | Benzoheterocyclic compounds | OTSUKA PHARMA CO LTD (JP) | 1997-08-20 | — | — | CN | disclosed |
| US-5358949-A | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| EP-0093945-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1988-11-23 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| US-4495192-A | HYPOTENSIVE AGENTS; VASODILATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1985-01-22 | — | — | US | disclosed |
| EP-0093945-A2 | 1,4-Dihydropyridine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | MC4R, MC3R, MC1R | SLC6A3 534/4885SIGMAR1 117/4885MAOA 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.